In vitro endothelial cell activation and inflammatory responses in end-stage heart failure

Journal of Applied Physiology

Volumn 101, Issue 5, 2006, Pages 1466-1473

  Hoare, Ginette S ^a   Birks, Emma J ^a   Bowles, Christopher ^a   Marczin, Nandor ^a   Yacoub, Magdi H ^a  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Adhesion molecule; Bioactivity; Cytokine; Inflammation

Indexed keywords

CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE; HEART GRAFT; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; INFLAMMATION; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SERUM;

ADULT; CELLS, CULTURED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; E-SELECTIN; ENDOTHELIUM, VASCULAR; FEMALE; HEART FAILURE, CONGESTIVE; HEART TRANSPLANTATION; HUMANS; I-KAPPA B PROTEINS; INTERLEUKIN-10; MALE; MIDDLE AGED; NF-KAPPA B; PULMONARY ARTERY; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33751198282     PISSN: 87507587     EISSN: 15221601     Source Type: Journal    
DOI: 10.1152/japplphysiol.01497.2005     Document Type: Article

References (44)

1. Aderka D, Engelmann H, Sherer-Avni Y, Hornik V, Galil A, Sarov B, and Wallach D. Variation in serum levels of the soluble TNF receptors among healthy individuals. Lymphokine Cytokine Res 11: 157-159, 1992.
2. Agnoletti L, Curello S, Bachetti T, Malacarne F, Gaia G, Comini L, Volterrani M, Bonetti P, Parrinello G, Cadei M, Grigolato PG, and Ferrari R. Serum from patients with severe heart failure downregulates eNOS and is proapoptotic: role of tumor necrosis factor-α. Circulation 100: 1983-1991, 1999.
3. Anker SD and Coats AJ. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 86: 123-130, 2002.
4. Aukrust P, Ueland T, Lien E, Bendtzen K, Muller F, Andreassen AK, Nordoy I, Aass H, Espevik T, Simonsen S, Froland SS, and Gullestad L. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 83: 376-382, 1999.
5. Birks EJ, Latif N, Owen V, Bowles C, Felkin LE, Mullen AJ, Khaghani A, Barton PJ, Polak JM, Pepper JR, Banner NR, and Yacoub MH. Quantitative myocardial cytokine expression and activation of the apoptotic pathway in patients who require left ventricular assist devices. Circulation 104: 233-240, 2001.
6. Bozkurt B, Kribbs SB, Clubb FJ Jr, Michael LH, Didenko VV, Hornsby PJ, Seta Y, Oral H, Spinale FG, and Mann DL. Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats. Circulation 97: 1382-1391, 1998.
7. Bryant D, Becker L, Richardson J, Shelton J, Franco F, Peshock R, Thompson M, and Giroir B. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-α. Circulation 97: 1375-1381, 1998.
8. Chung ES, Packer M, Lo KH, Fasanmade AA, and Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107: 3133-3140, 2003.
9. Colombo PC, Ashton AW, Celaj S, Talreja A, Banchs JE, Dubois NB, Marinaccio M, Malla S, Lachmann J, Ware JA, and Le Jemtel TH. Biopsy coupled to quantitative immunofluorescence: a new method to study the human vascular endothelium. J Appl Physiol 92: 1331-1338, 2002.
10. Colombo PC, Banchs JE, Celaj S, Talreja A, Lachmann J, Malla S, Dubois NB, Ashton AW, Latif F, Jorde UP, Ware JA, and LeJemtel TH. Endothelial cell activation in patients with decompensated heart failure. Circulation 111: 58-62, 2005.
11. Denk A, Goebeler M, Schmid S, Berberich I, Ritz O, Lindemann D, Ludwig S, and Wirth T. Activation of NF-κB via the IκB kinase complex is both essential and sufficient for proinflammatory gene expression in primary endothelial cells. J Biol Chem 276: 28451-28458, 2001.
12. Deswal A, Bozkurt B, Seta Y, Parilti-Eiswirth S, Hayes FA, Blosch C, and Mann DL. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation 99: 3224-3226, 1999.
13. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, and Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103: 2055-2059, 2001.
14. Edelstein LC, Pan A, and Collins T. Chromatin modification and the endothelial-specific activation of the E-selectin gene. J Biol Chem 280: 11192-11202, 2005.
15. Engelberts I, Stephens S, Francot GJ, van der Linden CJ, and Buurman WA. Evidence for different effects of soluble TNF-receptors on various TNF measurements in human biological fluids. Lancet 338: 515-516, 1991.
16. Fortenberry JD, Huber AR, and Owens ML. Inotropes inhibit endothelial cell surface adhesion molecules induced by interleukin-1β. Crit Care Med 25: 303-308, 1997.
17. Frantz S, Fraccarollo D, Wagner H, Behr TM, Jung P, Angermann CE, Ertl G, and Bauersachs J. Sustained activation of nuclear factor κB and activator protein 1 in chronic heart failure. Cardiovasc Res 57: 749-756, 2003.
18. Gerain J, Lienard D, Pampallona S, Baumgartner M, Ruegg C, Buurman WA, Eggermont A, and Lejeune F. Systemic release of soluble TNF receptors after high-dose TNF in isolated limb perfusion. Cytokine 9: 1034-1042, 1997.
19. Ghersa P, Hooft VH, Whelan J, Cambet Y, Pescini R, and DeLamarter JF. Inhibition of E-selectin gene transcription through a cAMP-dependent protein kinase pathway. J Biol Chem 269: 29129-29137, 1994.
20. Habib FM, Springall DR, Davis GJ, Oakley CM, Yacoub MH, Polak JM. Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet 347: 1129-1130, 1996.
21. Katz SD, Hryniewicz K, Hriljac I, Balidemaj K, Dimayuga C, Hudaihed A, and Yasskiy A. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation 111: 310-314, 2005.
22. Kubota T, McTiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP, Demetris AJ, and Feldman AM. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 81: 627-635, 1997.
23. Levine B, Kalman J, Mayer L, Fillit HM, and Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323: 236-241, 1990.
24. Lisinski TJ and Furie MB. Interleukin-10 inhibits proinflammatory activation of endothelium in response to Borrelia burgdorferi or lipopolysaccharide but not interleukin-1beta or tumor necrosis factor alpha. J Leukoc Biol 72: 503-511, 2002.
25. Lisman KA, Stetson SJ, Koerner MM, Farmer JA, and Torre-Amione G. The role of tumor necrosis factor alpha blockade in the treatment of congestive heart failure. Congest Heart Fail 8: 275-279, 2002.
26. Meacock S, Pescini-Gobert R, DeLamarter JF, and Hooft VH. Transcription factor-induced, phased bending of the E-selectin promoter. J Biol Chem 269: 31756-31762, 1994.
27. Noble KE, Harkness D, and Yong KL. Interleukin 10 regulates cellular responses in monocyte/endothelial cell co-cultures. Br J Haematol 108: 497-504, 2000.
28. Ollivier V, Parry GC, Cobb RR, de Prost D, and Mackman N. Elevated cyclic AMP inhibits NF-κB-mediated transcription in human monocytic cells and endothelial cells. J Biol Chem 271: 20828-20835, 1996.
29. Pagani FD, Baker LS, His C, Knox M, Fink MP, and Visner MS. Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-α in conscious dogs. J Clin Invest 90: 389-398, 1992.
30. Parks E, Lukacs NW, Strieter RM, and Kunkel SL. Chemokine expression in endothelial cells and monocytes is differentially regulated. Pathobiology 66: 64-70, 1998.
31. Parry GC and Mackman N. Role of cyclic AMP response element-binding protein in cyclic AMP inhibition of NF-κB-mediated transcription. J Immunol 159: 5450-5456, 1997.
32. Pober JS, Slowik MR, De Luca LG, and Ritchie AJ. Elevated cyclic AMP inhibits endothelial cell synthesis and expression of TNF-induced endothelial leukocyte adhesion molecule-1, and vascular cell adhesion molecule-1, but not intercellular adhesion molecule-1. J Immunol 150: 5114-5123, 1993.
33. Rossig L, Haendeler J, Mallat Z, Hugel B, Freyssinet JM, Tedgui A, Dimmeler S, and Zeiher AM. Congestive heart failure induces endothelial cell apoptosis: protective role of carvedilol. J Am Coll Cardiol 36: 2081-2089, 2000.
34. Saccani S, Pantano S, and Natoli G. Two waves of nuclear factor κB recruitment to target promoters. J Exp Med 193: 1351-1359, 2001.
35. Saccani S, Pantano S, and Natoli G. p38-Dependent marking of inflammatory genes for increased NF-κB recruitment. Nat Immun 3: 69-75, 2002.
36. Schottelius AJ, Mayo MW, Sartor RB, and Baldwin ASJ. Interleukin-10 signaling blocks inhibitor of κB kinase activity and nuclear factor κB DNA binding. J Biol Chem 274: 31868-31874, 1999.
37. Sironi M, Munoz C, Pollicino T, Siboni A, Sciacca FL, Bernasconi S, Vecchi A, Colotta F, and Mantovani A. Divergent effects of interleukin-10 on cytokine production by mononuclear phagocytes and endothelial cells. Eur J Immunol 23: 2692-2695, 1993.
38. Sivasubramanian N, Coker ML, Kurrelmeyer KM, MacLellan WR, DeMayo FJ, Spinale FG, and Mann DL. Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation 104: 826-831, 2001.
39. Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB, and Mann DL. Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart. Circulation 93: 704-711, 1996.
40. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, and Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor α in vitro and in vivo. Proc Natl Acad Sci USA 89: 4845-4849, 1992.
41. Vermeulen L, De Wilde G, Van Damme P, Vanden Berghe W, and Haegeman G. Transcriptional activation of the NF-κB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). EMBO J 22: 1313-1324, 2003.
42. Vora M, Romero LI, and Karasek MA. Interleukin-10 induces E-selectin on small and large blood vessel endothelial cells. J Exp Med 184: 821-829, 1996.
43. Yamaoka M, Yamaguchi S, Okuyama M, and Tomoike H. Antiinflammatory cytokine profile in human heart failure: behavior of interleukin-10 in association with tumor necrosis factor-α. Jpn Circ J 63: 951-956, 1999.
44. Yokoyama T, Nakano M, Bednarczyk JL, McIntyre BW, Entman M, and Mann DL. Tumor necrosis factor-α provokes a hypertrophic growth response in adult cardiac myocytes. Circulation 95: 1247-1252, 1997.